Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

Industry

Displaying 1 to 10 of 17 Posts . Displaying 10 of Posts . Page of 2 . Go To Page: . Per Page: . . . View All Sort By: .

FDA Approves ETICOVO™ (etanercept-ykro), Samsung Bioepis' Second Anti-TNF Medicine in the United States

Samsung Bioepis expands autoimmune portfolio in the United States with FDA approval of ETICOVO™ (etanercept-ykro), a biosimilar referencing ENBREL®i (etanercept). INCHEON, Korea – As of April 2019 – Samsung Bioepis Co., Ltd. today announced that the US Food and Drug Administration (FDA) has approved ETICOVO™ (etanercept-ykro), a biosimilar referencing ENBREL® (etanercept), across all eligible indications for the treatment of rheumatoid arthritis, ankylosing...

Read More

AbbVie Announces Approval of SKYRIZI™ for the Treatment of Psoriasis in US, Canada, Europe and Japan

AbbVie Announces Approval of SKYRIZI™ for the Treatment of Psoriasis in US, Canada and Japan AbbVie, a research-based global biopharmaceutical company, announced on March 26, 2019 that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved SKYRIZI™, an interleukin-23 (IL-23) inhibitor, for the treatment of plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis in adult patients who have an inadequate response to...

Read More

Ortho Dermatologics Receives FDA Approval of Duobriitm (Halobetasol Propionate and Tazarotene) Lotion 0.01%/0.045% for Plaque Psoriasis in Adults

Ortho Dermatologics Receives FDA Approval of Duobriitm (Halobetasol Propionate and Tazarotene) Lotion 0.01%/0.045% for Plaque Psoriasis in Adults First and Only Topical Lotion Combining Halobetasol Propionate and Tazarotene in One Formulation1 Safety was Established in a Long-Term Study of Up to 24 Weeks of Continuous Use and up to 52 Weeks of As-Needed Use2 RALEIGH, N.C., Apr. 25, 2019 – Ortho Dermatologics, one of the largest prescription dermatology health care businesses in the...

Read More

CIMZIA® (certolizumab pegol) is Now the First and Only U.S. FDA-Approved Treatment for Non-Radiographic Axial Spondyloarthritis

CIMZIA® (certolizumab pegol) is Now the First and Only U.S. FDA-Approved Treatment for Non-Radiographic Axial Spondyloarthritis Patients living with non-radiographic axial spondyloarthritis, an often undiagnosed, chronic, painful and debilitating disease, now have an approved, clinically validated treatment FDA approval was based on the C-AXSPAND Phase 3 study in adults with non-radiographic axial spondyloarthritis, which demonstrated rapid and major improvement response with...

Read More

Novartis first-in-class Cosentyx® approved in China for psoriasis patients

Novartis first-in-class Cosentyx® approved in China for psoriasis patients China Health Authority NMPA approved Cosentyx® (secukinumab) for moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy Cosentyx is the first biologic approved in China that specifically inhibits interleukin-17A (IL-17A), a cornerstone cytokine involved in the inflammation of psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis...

Read More

AbbVie Announces First Regulatory Approval of SKYRIZI™ (risankizumab) for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis and Psoriatic Arthritis in Japan

AbbVie Announces First Regulatory Approval of SKYRIZI™ (risankizumab) for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis and Psoriatic Arthritis in Japan This marks the first regulatory approval globally for SKYRIZI™ (risankizumab) SKYRIZI is a humanized immunoglobulin G1 (IgG1) monoclonal antibody designed to selectively inhibit IL-23 by binding to its p19 subunit[1] NORTH CHICAGO, Ill., March 26, 2019 /PRNewswire/...

Read More

TV Host and Fashion Journalist Louise Roe Shares Her Personal Story With Plaque Psoriasis as Part of INSIDE PERSPECTIVE Campaign

TV host and fashion journalist Louise Roe launches the INSIDE PERSPECTIVE campaign with Celgene Corporation (NASDAQ: CELG) and Otezla® (apremilast), and for the first time, shares her inside story with psoriasis, a condition she has been living with for more than a decade.

Read More

Sun Pharma Announces the Availability of ILUMYATM (tildrakizumab-asmn) in the United States for the Treatment of Moderate-to-Severe Plaque Psoriasis

Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) today announced that moderate-to-severe psoriasis treatment ILUMYATM (tildrakizumab-asmn) 100 mg/mL is now available in the United States. ILUMYATM is an injectable interleukin-23 (IL-23) inhibitor approved by the FDA for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Read More

The European Commission approves Almirall’s ILUMETRI® (tildrakizumab) for moderate-to-severe chronic plaque psoriasis

Almirall, S.A. announced today that the European Commission (EC) has approved ILUMETRI® (tildrakizumab), a humanized, high-affinity IL-23p19 monoclonal antibody, for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy1.

Read More

Sienna Biopharmaceuticals Completes Maximal Use Safety Study of SNA-120 in Patients with Psoriasis

Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA), a clinical-stage medical dermatology and aesthetics company, today announced results from a Phase 1b maximal use (MUse) pharmacokinetic (PK) and safety study of SNA-120 (pegcantratinib), a Phase 2b drug candidate being evaluated as a topical, nonsteroidal therapy to treat itch (pruritus) associated with psoriasis.

Read More
UPCOMING EVENT

Hot topics and challenging cases in psoriasis: A focus on pustular, biosimilars, pediatrics and treating in under-served areas

Monday, june 10, 2019
1:30 – 4:30 pm
milan, italy
Register Now

Stay informed

Join the email list to receive the latest information on psoriasis meetings, manuscripts and research.
SUBSCRIBE

This website uses cookies. Please ensure your cookies are enabled. 
OK